Company intelligence / Profile preview

Nubbo

New York, New York, United Statesnubbo.io ↗

Ownership: Private
Development stage: Other

Overview

Nuvation Bio recently received FDA approval for IBTROZI™ (taletrectinib) as a next-generation oral treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The pivotal TRUST program demonstrated high response rates and durable benefit including intracranial activity. Other pipeline programs include safusidenib in phase 2 trials targeting mIDH1-mutant glioma, innovative drug-drug conjugates such as NUV‑1511, and the BD2-selective BET inhibitor NUV‑868.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Nubbo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nubbo.

Explore the full profile